Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BCDA
stocks logo

BCDA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.170
-32%
--
--
-0.230
-61.02%
--
--
-0.230
-42.5%
Estimates Revision
The market is revising No Change the revenue expectations for BioCardia, Inc. (BCDA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -28.64%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-1.23%
In Past 3 Month
Stock Price
Go Down
down Image
-28.64%
In Past 3 Month
Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is 15.50 USD with a low forecast of 6.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is 15.50 USD with a low forecast of 6.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.470
sliders
Low
6.00
Averages
15.50
High
25.00
Current: 1.470
sliders
Low
6.00
Averages
15.50
High
25.00
HC Wainwright & Co.
Joseph Pantginis
Strong Buy
Reiterates
$25
2024-12-18
Reason
HC Wainwright & Co.
Joseph Pantginis
Price Target
$25
2024-12-18
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for BioCardia Inc (BCDA.O) is -1.71, compared to its 5-year average forward P/E of -3.03. For a more detailed relative valuation and DCF analysis to assess BioCardia Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.03
Current PE
-1.71
Overvalued PE
-0.54
Undervalued PE
-5.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.25
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.11
Undervalued EV/EBITDA
-2.38

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
120.23
Current PS
0.00
Overvalued PS
310.36
Undervalued PS
-69.90
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areBuying! The selling amount has increased 17714.87% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areBuying! The selling amount has increased 17714.87% over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

BCDA News & Events

Events Timeline

(ET)
2025-12-03
08:20:00
BioCardia Appoints Marvin Slosman to Board of Directors
select
2025-11-24 (ET)
2025-11-24
08:35:51
BioCardia Names Farhan Shahab as Vice President of Quality
select
2025-11-10 (ET)
2025-11-10
08:40:42
BioCardia Enrolls First Patient at Henry Ford Health for Phase 3 CardiAMP Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
12-03Newsfilter
BioCardia Elects Marvin Slosman to Board of Directors
  • New Board Appointment: BioCardia announced the election of Marvin Slosman to its Board of Directors effective December 2, 2025, bringing deep expertise in interventional cardiology that is expected to drive innovation and market expansion in cardiovascular disease treatment.
  • Rich Leadership Experience: Slosman, who previously served as CEO of InspireMD and held senior commercial leadership roles at Johnson & Johnson, GE Healthcare, and Baxter International, brings extensive market development and product commercialization experience that will aid BioCardia's strategic growth.
  • Gratitude to Former Director: BioCardia expressed appreciation for departing board member Richard Krasno, who provided guidance during key milestones, particularly in the FDA approval of the CardiAMP cell therapy and the Morph DNA product.
  • Strategic Company Development: The appointment of Slosman is expected to significantly support BioCardia's clinical value creation and global market expansion, further advancing the company's innovative solutions for treating cardiovascular and pulmonary diseases.
[object Object]
Preview
5.0
11-24Yahoo Finance
BioCardia Enhances Leadership Team by Appointing Farhan Shahab as Vice President of Quality

  • New Appointment: BioCardia, Inc. has appointed Farhan Shahab as Vice President of Quality, bringing over 25 years of experience in quality management and regulatory affairs from various companies in the healthcare sector.

  • Previous Experience: Shahab's prior roles include Vice President of Quality and Regulatory at Welldoc, Senior Director at Intuity Medical, and Director at Moximed, showcasing a strong background in product quality management across multiple medical device categories.

  • CEO's Statement: Peter Altman, CEO of BioCardia, expressed confidence in Shahab's expertise, stating that his leadership and experience will enhance the company's ability to commercialize investigational products.

  • Company Overview: BioCardia specializes in cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, with ongoing development of clinical-stage product candidates and innovative biotherapeutic delivery platforms.

[object Object]
Preview
9.5
11-13NASDAQ.COM
BioCardia, Inc. Reports Smaller Q3 Loss, Surpassing Expectations

  • Earnings Performance: BioCardia, Inc. reported a loss of $1.48 million for the third quarter, an improvement from a loss of $1.74 million in the same period last year.

  • Earnings Per Share: The company's earnings per share (EPS) were -$0.24, compared to -$0.61 in the previous year, beating analysts' expectations of -$0.25 per share.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BioCardia Inc (BCDA) stock price today?

The current price of BCDA is 1.47 USD — it has increased 3.52 % in the last trading day.

arrow icon

What is BioCardia Inc (BCDA)'s business?

BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow, such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia. Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome. Its CardiAMP autologous and CardiALLO allogeneic cell therapies are the Company’s biotherapeutic platforms with three clinical stage product candidates in development. These therapies are enabled by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.

arrow icon

What is the price predicton of BCDA Stock?

Wall Street analysts forecast BCDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCDA is 15.50 USD with a low forecast of 6.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BioCardia Inc (BCDA)'s revenue for the last quarter?

BioCardia Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is BioCardia Inc (BCDA)'s earnings per share (EPS) for the last quarter?

BioCardia Inc. EPS for the last quarter amounts to -0.24 USD, decreased -60.66 % YoY.

arrow icon

What changes have occurred in the market's expectations for BioCardia Inc (BCDA)'s fundamentals?

The market is revising No Change the revenue expectations for BioCardia, Inc. (BCDA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -28.64%.
arrow icon

How many employees does BioCardia Inc (BCDA). have?

BioCardia Inc (BCDA) has 17 emplpoyees as of December 05 2025.

arrow icon

What is BioCardia Inc (BCDA) market cap?

Today BCDA has the market capitalization of 15.07M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free